ArticleEvidence-based complementary and alternative medicine : eCAM2021
Extracts of
Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Comparison of Lignan Contents and Antioxidant Activities in Five Perilla (Preventive nutrition and food science · 2026Article
- Bioactive compounds from Perilla frutescens modulate multiple cell death pathways and signaling networks in cancer therapy.Frontiers in pharmacology · 2026Review
- Article
- Downregulation of long noncoding RNA B4GALT1-AS1 is associated with breast cancer development.Scientific reports · 2024Article
- Assessing the Antioxidant Properties, In Vitro Cytotoxicity and Antitumoral Effects of Polyphenol-RichAntioxidants (Basel, Switzerland) · 2023Article
- Review
- Therapeutic Effects of Perilla Phenols in Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Article
- The Role and Mechanism ofMolecules (Basel, Switzerland) · 2023Review
- An Ethanol Extract ofMolecules (Basel, Switzerland) · 2023Article
- Applications ofAntioxidants (Basel, Switzerland) · 2023Review
- Luteolin-rich fraction fromFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yes-associated protein (YAP)/WW domain-containing transcription factor (TAZ) is critical for cell proliferation, survival, and self-renewal. It has been shown to play a crucial oncogenic role in many different types of tumors. In this study, we investigated the antitumor effect of the extracts of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.